Fig. 7: In vitro ROS generation and nanocatalytic therapeutic performance of BCSO NSs against B16F10 cells. | Nature Communications

Fig. 7: In vitro ROS generation and nanocatalytic therapeutic performance of BCSO NSs against B16F10 cells.

From: Two-dimensional superlattice nanocatalysts unlock multimodal energy transformation-driven catalytic therapy

Fig. 7

Viability of (a) HUVEC and (b) B16F10 cells after incubation with various concentrations of BCSO NSs for different time (n = 6 independent biological samples, mean ± s.d., two-way ANOVA). c FCM images and d CLSM images of B16F10 cells after incubation with FITC-labeled BCSO NSs. e CLSM images of DCFH-DA-stained B16F10 cells under various treatments. f Intracellular ·O2− level of B16F10 cells after different treatments. g Live/dead staining of B16F10 cells in different groups. h Cytotoxicity assays of B16F10 cells across groups (n = 6 independent biological samples, mean ± s.d., one-way ANOVA). i FCM images of the apoptosis of B16F10 cells and (j) the corresponding quantitative analysis of apoptosis percentages in different groups (n = 3 independent biological samples, mean ± s.d., one-way ANOVA with Dunnett’s test). k CLSM images of JC-1-stained B16F10 cells following different treatments. l Schematic of the sono-piezoelectric nanocatalytic therapy (Created with BioRender.com). Source data are provided as a Source Data file.

Back to article page